Skip to main
LUNG
LUNG logo

Pulmonx (LUNG) Stock Forecast & Price Target

Pulmonx (LUNG) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 50%
Buy 10%
Hold 30%
Sell 10%
Strong Sell 0%

Bulls say

Pulmonx Corp's financial performance demonstrates a strong upward trajectory, with total revenue for 2024 reaching $83.8 million, reflecting a 22% increase from the previous year. The company also reported significant revenue growth in international markets, with international revenue rising by 20% to $27.3 million, indicating successful global market penetration. Additionally, advancements in technology and expanding reimbursement coverage are likely to enhance adoption rates of Pulmonx's products, thereby supporting continued financial growth and improved patient outcomes.

Bears say

Pulmonx Corp's financial outlook appears cautious as gross profit for the latest quarter decreased slightly, reflecting a gross margin dip from 75% to 74%, which could indicate potential pricing pressures or higher costs impacting profitability. The company also reported a decline in cash reserves, with a reduction from $107.8 million to $101.5 million within just three months, suggesting challenges in managing cash flow and potentially limiting growth initiatives. Furthermore, the company's status as a small-cap entity introduces volatility and risk that may deter investors, particularly in a sector characterized by rising costs and significant competition amid aging populations and increasing healthcare burdens.

Pulmonx (LUNG) has been analyzed by 10 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 10% recommend Buy, 30% suggest Holding, 10% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Pulmonx (LUNG) Forecast

Analysts have given Pulmonx (LUNG) a Buy based on their latest research and market trends.

According to 10 analysts, Pulmonx (LUNG) has a Buy consensus rating as of Jul 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Pulmonx (LUNG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.